BridgeBio Oncology Therapeutics, Inc. (BBOT) Financial Statements (2026 and earlier)

Company Profile

Business Address 256 E. GRAND AVENUE, SUITE 104
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:425,5001,698
Cash and cash equivalent373,6871,698
Short-term investments51,773 
Other undisclosed cash, cash equivalents, and short-term investments40 
Prepaid expense  252
Other undisclosed current assets6,896 
Total current assets:432,3961,950
Noncurrent Assets
Operating lease, right-of-use asset2,330 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization956 
Long-term investments and receivables  
Long-term investments  
Asset, held-in-trust  192,449
Restricted cash and investments132 
Other noncurrent assets12,567 
Other undisclosed noncurrent assets  25
Total noncurrent assets:15,985192,474
TOTAL ASSETS:448,381194,424
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,034120
Accounts payable1,374 
Accrued liabilities6,660120
Debt534 
Other undisclosed current liabilities26,47368
Total current liabilities:35,041188
Noncurrent Liabilities
Liabilities, other than long-term debt2,244 
Operating lease, liability2,244 
Other undisclosed noncurrent liabilities  5,520
Total noncurrent liabilities:2,2445,520
Total liabilities:37,2855,708
Equity
Equity, attributable to parent, including:411,096(3,733)
Common stock8 
Additional paid in capital767,639 
Accumulated other comprehensive income (loss)16 
Accumulated deficit(356,567)(3,733)
Other undisclosed equity, attributable to parent  1
Other undisclosed equity  192,449
Total equity:411,096188,717
TOTAL LIABILITIES AND EQUITY:448,381194,424

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
Revenues11,3436
Net investment income11,343 
Revenues, excluding interest and dividends 6
Gross profit:11,3436
Operating expenses(145,819)(584)
Other undisclosed operating loss(11,343)(6)
Operating loss:(145,819)(584)
Nonoperating income11,7758,184
Investment income, nonoperating 8,449
Net income (loss) attributable to parent:(134,044)7,600
Preferred stock dividends and other adjustments  (16,608)
Net loss available to common stockholders, diluted:(134,044)(9,009)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
Net income (loss):(134,044)7,600
Comprehensive income (loss):(134,044)7,600
Other undisclosed comprehensive loss, net of tax, attributable to parent(332) 
Comprehensive income (loss), net of tax, attributable to parent:(134,376)7,600

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: